Sibel Yilmaz advises on all aspects of competition law, foreign investment and foreign subsidies screening, with a focus on the life sciences, technology and private equity sectors.

Sibel has particular expertise in the life sciences sector and has been involved in some of the industry's most high profile matters in recent years, including representing Novartis on its $30 billion acquisition of GSK’s oncology business, advising Takeda on its sale of certain respiratory products to AstraZeneca and representing clients in several investigations relating to alleged excessive prices and other non-competitive practices in the life science sector.

Sibel is ranked among the world's top antitrust practitioners by Global Competition Review, who included her in their most recent 40 Under 40 survey, as well as Chambers Global. She is described as "a brilliant and promising lawyer, who is highly recommended for complex merger work” and “an exceptional talent”, "absolutely a tip for the top."

Sibel received her LL.M. in Law and Economics from the University of Rotterdam and Master of Law from Stockholm University and is admitted to practice in Belgium and Sweden.